logo
The Healthcare Industry's Climate Time Bomb

The Healthcare Industry's Climate Time Bomb

Medscape3 days ago

All stakeholders in healthcare now aim to make the sector greener, and several ongoing initiatives show that real changes are possible.
Recently, the 2024 Global Report from The Lancet Countdown issued an urgent warning that human health is threatened by climate inaction. Experts have cautioned that we have reached a 'point of no return' as global warming systematically undermines public health worldwide.
However, what happens when the health system itself is polluted? Data from the Ministry of Health show that the healthcare sector accounts for approximately 4.4% of net global greenhouse gas emissions, roughly 1.6 gigatons of CO 2 . What is being done about this?
Sector Emissions
According to a new report by Health Care Without Harm, in collaboration with Arup, 'The Health Sector's Climate Footprint: How the Health Sector Contributes to the Global Climate Crisis: Opportunities for Action,' the largest contributors are the United States (546 million metric tons of CO 2 equivalent), China (342 million metric tons of CO 2 equivalent), and the European Union (248 million metric tons of CO 2 equivalent). More than half of this footprint stems from energy consumption, such as electricity, gas, steam, and air conditioning systems, combined with operational emissions.
Other significant sources included agriculture (9%, including food service in health centres and cotton cultivation for surgical gowns), pharmaceuticals, and chemicals (5%, excluding production energy transport [7%] and waste treatment [3%]). A further 1% of the health sector's global climate footprint, or nearly 4 million metric tons of emissions, is derived from anaesthetic gases (0.6%) and metered-dose inhalers (0.3%).
The ECODES report 'Reduction of GHG Emissions in the Healthcare Sector Focus on Scope 3 of the Carbon Footprint' categorises emissions into three types of scopes. According to Health Care Without Harm, Scope 1 covers direct emissions from daily operations, such as burning fossil fuels for heating, cooling, and anaesthetic gases; owned vehicle exhaust; and fugitive emissions from air conditioning and cold storage systems, accounting for approximately 17% of the total. Scope 2 covers indirect emissions from the acquisition and consumption of electrical energy by healthcare facilities, including electricity, steam, refrigeration, and heating, accounting for approximately 12% of the total emissions. Scope 3, the largest category, includes the production, distribution, and disposal of goods and services consumed by the sector, such as medical supplies, medicines, equipment, and associated transport.
Waste Management
Several initiatives have been launched from international, national, regional, public, and private perspectives. The Global Green and Healthy Hospitals Network (GGHH) includes more than 1900 members in over 80 countries, representing approximately 70,000 hospitals. GGHH supports its members in conducting sustainability projects by providing access to a wide range of exclusive and innovative tools and resources.
In May 2025, GGHH published a report on the 'Chemical recycling of plastic waste from the healthcare sector,' evaluating recycling technologies, toxic by-products, carbon footprint, and economic viability to identify the best options for healthcare plastic waste.
In Spain, the AIMPLAS Technological Centre in Valencia, Spain, is engaged in circular economy and decarbonisation projects, producing biocompatible, biodegradable, injectable, and resorbable materials such as polylactic acid (PLA) and their copolymer poly(lactide-co-glycolide), poly(ε-caprolactone) — PCL — and PLA-PCL, using various technologies such as synthesis and reactive extrusion. These biopolymers offer sustainable alternatives to conventional plastics and significantly reduce non-biodegradable pollution.
In 2025, Granada-based Athisa opened Spain's first sustainable healthcare waste treatment plant in Ciudad Real, Spain. One of its milestones is the management of solid cytostatic waste, which, unlike traditional incineration methods, uses advanced oxidation with an ozone-like oxidant that does not generate hazardous waste. This alternative avoids the emission of greenhouse gases and the generation of hazardous ash, which is typically deposited in specialised landfills, representing a more sustainable option than incineration.
Carbon Reduction
The Ministry of Health launched the National Information System on the Healthcare Carbon Footprint. This tool collects and provides data on the calculation of atmospheric greenhouse gas emissions from processes that occur in different healthcare centres during a given year.
In March 2025, the Ministry resumed carbon footprint workshops on the carbon footprint in healthcare centres as part of the Strategic Health and Environment Plan. From Health #ForTheClimate (ECODES) on this key initiative for decarbonisation of the healthcare sector.
In a public-private partnership, the MAPIC+s project (ECODES and GSK) aims to reduce the carbon footprint of the National Health System and drive environmental sustainability. MAPIC+s offers a roadmap for healthcare organisations by integrating sustainability into strategic plans, forming sustainability committees, replacing single-use materials, and reducing fluorinated gases, with case studies from Spain.
Eli Lilly and Company and DHL Freight launched a project to reduce CO₂ emissions on international routes. By using biodiesel vehicles and carefully planning routes, they aim to lower emissions from shipments between Eli Lilly and Company's Alcobendas plant in Madrid and destinations in Belgium and the Netherlands.
Anaesthetic Emissions
The pharmaceutical industry is also working to reduce the environmental impact of anaesthetic gases and metered-dose inhalers. Efforts are underway to accelerate the shift to near-zero carbon propellant inhalers, with the next generation expected to be launched by 2025.
However, as Carlos Almonacid, MD, vice president of the Spanish Society of Pulmonology and Thoracic Surgery, emphasised at a recent press conference, good clinical control offers both environmental and economic benefits. This leads to a reduced use of rescue inhalers, which typically have a higher carbon footprint, thereby supporting healthcare system sustainability. It also conserves healthcare resources and minimises patient travel to medical centres, thereby lowering pollution associated with transportation. These factors, in turn, strengthen the doctor-patient relationship, improve treatment adherence, and build trust in the healthcare system.
In January 2025, the Ministry announced the 'Green Anaesthesia' working group; the objective is to continue advancing the sustainability of the healthcare system and to develop a document of best practices and solutions to achieve 'better anaesthesia for patients and the planet,' an estimated 2% of the National Health System's carbon footprint and approximately 10% of the direct emissions from health centres.
Mónica García, MD, Minister of Health of Spain, and a public-sector anaesthesiologist for 20 years, reaffirmed her 'conviction that it is possible to reduce anaesthesia's environmental impact without compromising care quality, patient health, or professional practice. That is why we convened this working group.'
Digital Health
Another major step in reducing the environmental footprint is moving towards digital health. However, experts caution that the environmental impact of technologies such as artificial intelligence must also be considered.
Speaking to El Medico Interactivo , Miguel Ángel Casermeiro, secretary of the Spanish Association for Environmental Impact Assessment, noted that the digital sector is expected to become one of the main consumers of energy, as shown by the rising energy demand in this field.
Many data centre projects are currently underway in Spain, positioning the country as a key player in the global management of digital resources. 'This new digital health landscape must also be assessed in terms of its energy use,' he said.
At the same time, Casermeiro emphasised that 'Digital health will also yield significant savings in travel and information handling — potentially reducing diagnostic tests — leading to substantial savings for the National Health System.'
Similarly, Jaime del Barrio, MD, president of the Digital Health Association, told El Medico Interactivo that while 'digital health has environmental impacts throughout its life cycle, including production, transportation, operations, and end-of-life management. However, the development and implementation can have a positive effect, significantly reduce the carbon footprint, and making the healthcare sector more efficient.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy names 8 vaccine committee replacements, including COVID shot critic
Kennedy names 8 vaccine committee replacements, including COVID shot critic

Associated Press

time37 minutes ago

  • Associated Press

Kennedy names 8 vaccine committee replacements, including COVID shot critic

NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

timean hour ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store